References of "MAGIS, Delphine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailA novel CACNA1A mutation results in episodic ataxia with migrainous features without headache
MAGIS, Delphine ULg; Boon, Elles; Coppola, Gianluca et al

in Cephalalgia : An International Journal of Headache (2012)

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailAdvances and challenges in neurostimulation for headaches
MAGIS, Delphine ULg; Schoenen, Jean ULg

in Lancet Neurology (2012), 11(8), 708-719

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailNeurostimulation therapies for primary headache disorders: present and future
MAGIS, Delphine ULg; JENSEN, Rigmor; Schoenen, Jean ULg

in Current Opinion in Neurology (2012), 25(3), 269-276

Purpose of review Most pharmacological treatments of primary headache disorders are partially effective and have cumbersome side effects. Therapies with better efficacy and tolerance are needed ... [more ▼]

Purpose of review Most pharmacological treatments of primary headache disorders are partially effective and have cumbersome side effects. Therapies with better efficacy and tolerance are needed. Neurostimulation techniques may have this potential. This is an attempt to summarize the latest clinical trial results published in the field. Recent findings Hypothalamic deep brain stimulation is effective in drug-resistant chronic cluster headache (drCCH) but not riskless. Recent anatomical MRI studies indicate that the effective stimulation sites are rather widespread. Occipital nerve stimulation (ONS) seems to be effective in up to 76% of drCCH patients and its benefit long-lasting. A minority of patients are able to abandon preventive drugs. Its mechanism of action appears nonspecific. In chronic migraine, randomized controlled trials of ONS showed recently encouraging results, but long-term studies are missing. An ongoing sham-controlled trial suggests sphenopalatine ganglion neurostimulation (SPGS) efficacy in drCCH acute treatment, but possibly also in preventive therapy. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) modulate cortical excitability and connectivity. TMS could prevent headache when applied over the occipital cortex during the migraine aura. Repetitive TMS and tDCS have provided mixed results in a few small studies and warrant further trials. Summary Neurostimulation therapies inaugurate a new era in headache management and offer a promising alternative to medications. Future studies are necessary to provide evidence-based efficacy data, knowledge on their mode of action and information about their pharmaco-economic advantages. [less ▲]

Detailed reference viewed: 38 (0 ULg)
Full Text
Peer Reviewed
See detailLes migraines: des gènes à l'environnement
MAGIS, Delphine ULg; Schoenen, Jean ULg

in Revue Médicale de Liège (2012), 67(5-6), 349-358

Detailed reference viewed: 44 (6 ULg)
Peer Reviewed
See detailNeurosurgery for headaches
MAGIS, Delphine ULg

Conference (2012, March)

Detailed reference viewed: 4 (1 ULg)
Peer Reviewed
See detailNon invasive neurostimulation for headaches.
MAGIS, Delphine ULg

Conference (2012, March)

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailNeurostimulation dans l’algie vasculaire de la face.
MAGIS, Delphine ULg; FONTAINE, Denys

Conference (2011, October)

Detailed reference viewed: 8 (0 ULg)
See detailCase report discussion.
MAGIS, Delphine ULg

Conference (2011, October)

Full Text
Peer Reviewed
See detailSustained effeciveness of occipital nerve stimulation in drug-resistant chronic cluster headache
MAGIS, Delphine ULg; Gerardy, Pierre-Yves; Remacle, Jean-Michel et al

in Headache (2011)

Detailed reference viewed: 21 (11 ULg)
Peer Reviewed
See detailTeaching course: Pearls and pitfalls in headache electrophysiology
MAGIS, Delphine ULg

Conference (2011, June)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailHabituation of evoked responses is greater in patients with familial hemiplegic migraine than in controls: a contrast with the common forms of migraine.
Hansen, Jacob Moller; Bolla, Monica; Magis, Delphine ULg et al

in European Journal of Neurology (2011)

Background: Familial hemiplegic migraine (FHM) is a rare, dominantly inherited subtype of migraine with transient hemiplegia during the aura phase. Mutations in at least three different genes can produce ... [more ▼]

Background: Familial hemiplegic migraine (FHM) is a rare, dominantly inherited subtype of migraine with transient hemiplegia during the aura phase. Mutations in at least three different genes can produce the FHM phenotype. The mutated FHM genes code for ion transport proteins that animal and cellular studies have associated with disturbed ion homeostasis, altered cellular excitability, neurotransmitter release, and decreased threshold for cortical spreading depression. The common forms of migraine are characterized interictally by a habituation deficit of cortical and subcortical evoked responses that has been attributed to neuronal dysexcitability. FHM and the common forms of migraine are thought to belong to a spectrum of migraine phenotypes with similar pathophysiology, and we therefore examined whether an abnormal habituation pattern would also be found in FHM patients. Methods: In a group of genotyped FHM patients (five FHM-1, four FHM-2), we measured habituation of visual evoked potentials (VEP), auditory evoked potentials including intensity dependence (IDAP), the nociception-specific blink reflex (nsBR) and compared the results to a group of healthy volunteers (HV). Results: FHM patients had a more pronounced habituation during VEP (P = 0.025) and nsBR recordings (P = 0.023) than HV. There was no difference for IDAP, but the slope tended to be steeper in FHM. Conclusion: Contrary to the common forms of migraine, FHM patients are not characterized by a deficient, but rather by an increased habituation in cortical/brain stem evoked activities. These results suggest differences between FHM and the common forms of migraine, as far as central neuronal processing is concerned. [less ▲]

Detailed reference viewed: 23 (5 ULg)
Peer Reviewed
See detailNeurostimulation therapy in intractable headaches
Schoenen, Jean ULg; Allena, M; MAGIS, Delphine ULg

in Nappi; Moskowitz (Eds.) Handbook of Clinical Neurology (2011)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailTreatment of migraine: update on new therapies.
MAGIS, Delphine ULg; Schoenen, Jean ULg

in Current Opinion in Neurology (2011)

PURPOSE OF REVIEW: This review provides a comprehensive selection of the latest clinical trial results in antimigraine treatment. RECENT FINDINGS: The oral calcitonine gene-related peptide antagonist ... [more ▼]

PURPOSE OF REVIEW: This review provides a comprehensive selection of the latest clinical trial results in antimigraine treatment. RECENT FINDINGS: The oral calcitonine gene-related peptide antagonist telcagepant is efficacious in acute treatment. Compared to triptans, its efficacy is almost comparable but its tolerance is superior. The same is true for the 5HT-1F agonist lasmiditan, another agent devoid of vascular effects. Triptans, as other drugs, are more efficient if taken early but nonsteroidal anti-inflammatory drugs and analgesics remain useful for acute treatment, according to several meta-analyses. Single-pulse transcranial magnetic stimulation during the aura rendered more patients pain-free (39%) than sham stimulation (22%) in one study. Topiramate could be effective for migrainous vertigo, but it did not prevent transformation to chronic migraine in patients with high attack frequency. Onabotulinumtoxin A was effective for chronic migraine and well tolerated, but the therapeutic gain over placebo was modest; the clinical profile of responders remains to be determined before widespread use. Occipital nerve stimulation was effective in intractable chronic migraine with 39% of responders compared to 6% after sham stimulation. This and other neuromodulation techniques, such as sphenopalatine ganglion stimulation, are promising treatments for medically refractory patients but large controlled trials are necessary. One study suggests that outcome of patent foramen ovale closure in migraine might depend on anatomic and functional characteristics. SUMMARY: Drugs with a better efficacy or side-effect profile than triptans may soon become available for acute treatment. The future may also look brighter for some of the very disabled chronic migraineurs thanks to novel drug and neuromodulation therapies. [less ▲]

Detailed reference viewed: 61 (12 ULg)
Full Text
Peer Reviewed
See detailLa neurostimulation : quelle place dans les céphalées réfractaires?
MAGIS, Delphine ULg; SCHOENEN, Jean ULg

in Revue Médicale de Liège (2011), 66(2), 85-90

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailPeripheral nerve stimulation in chronic cluster headache.
MAGIS, Delphine ULg; Schoenen, Jean ULg

in Progress in Neurological Surgery (2011), 24

Cluster headache is well known as one of the most painful primary neurovascular headache. Since 1% of chronic cluster headache patients become refractory to all existing pharmacological treatments ... [more ▼]

Cluster headache is well known as one of the most painful primary neurovascular headache. Since 1% of chronic cluster headache patients become refractory to all existing pharmacological treatments, various invasive and sometimes mutilating procedures have been tempted in the last decades. Recently, neurostimulation methods have raised new hope for drug-resistant chronic cluster headache patients. The main focus of this chapter is on stimulation of the great occipital nerve, which has been the best evaluated peripheral nerve stimulation technique in drug-resistant chronic cluster headache, providing the most convincing results so far. Other peripheral nerve stimulation approaches used for this indication are also reviewed in detail. Although available studies are limited to a relatively small number of patients and placebo-controlled trials are lacking, existent clinical data suggest that occipital nerve stimulation should nonetheless be recommended for intractable chronic cluster headache patients before more invasive deep brain stimulation surgery. More studies are needed to evaluate the usefulness of supraorbital nerve stimulation and of vagus nerve stimulation in management of cluster headaches. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailThe California Verbal Learning Test and other standard clinical neuropsychological tests to predict conversion from mild memory impairment to dementia.
Lekeu, Françoise ULg; Magis, Delphine ULg; Marique, Patricia et al

in Journal of Clinical & Experimental Neuropsychology (2010), 20

Detailed reference viewed: 148 (17 ULg)
Full Text
Peer Reviewed
See detailSustained efficacy of occipital nerve stimulation in drug-resistant chronic cluster headache after up to 5 years treatment
Magis, Delphine ULg; Gérardy, Pierre-Yves; Remacle, Jean-Michel et al

in Journal of Headache & Pain (2010), 11(Suppl 1), 15

Background. Drug-resistant chronic cluster headache (drCCH) is a devastating condition for which various invasive procedures have been tempted without any satisfactory effect. Our prospective pilot study ... [more ▼]

Background. Drug-resistant chronic cluster headache (drCCH) is a devastating condition for which various invasive procedures have been tempted without any satisfactory effect. Our prospective pilot study of great occipital nerve stimulation (ONS) in 8 drCCH patients showed encouraging results at 15 months (1). Methods. We recruited 15 patients with drCCH according to the previously published criteria of intractability (2). They were implanted with suboccipital stimulators on the side of their headache. Long-term follow-up was achieved by questionnaires administered during a headache consultation and/or by telephone interviews. Results. One patient had an immediate post operative infection of the material. Mean time with ONS was 28.8 months (range 3-60 months). Nine of the 14 remaining patients were totally pain-free (64%), 2 patients had an improvement in frequency exceeding 90% and one patient a 89% amelioration. Two patients did not respond or described mild improvement. Intensity of residual attacks was not improved by ONS. Four patients (29%) were able to reduce their prophylaxis. Common technical problems were battery depletion (N=8/14, 57%) and material infection (N=3/15, 20%). Recurrent battery replacement (until 2/ year in one patient) is now avoided by the availability of rechargeable batteries. Clinical peculiarities associated with ONS were occurrence of infrequent contralateral attacks (N=5/14, 36%), and/or isolated ispilateral autonomic attacks (N=5/14, 36%). Rapid attack recurrence after stimulator switch off was reported by 7/12 improved patients (58%). Two patients found ONS-related paresthesias unbearable; one had his stimulator removed, the other switched it off though he was objectively ameliorated. Subjectively, nine patients are very satisfied by ONS and one patient moderately satisfied. Conclusions. Our long-term follow-up confirms the efficacy of ONS in drCCH, which remains a safe and well-tolerated technique. The occurrence of contralateral attacks and isolated autonomic attacks in nearly 50% of ONS responders may have therapeutic and pathophysiological implications. [less ▲]

Detailed reference viewed: 53 (3 ULg)